On June 23, 2020, the Board of Directors of PDS Biotechnology Corporation announced that Michael King will replace Janetta Trochimiuk as interim Principal Accounting Officer and Frank Bedu- Addo, Ph.D., as interim Principal Financial Officer. Mr. King, age 50, joined the Company in 2014 as the Chief Financial Officer. Mr. King helped take the Company public via a reverse merger with Edge Therapeutics Inc. in March 2019 and has continued to serve as a financial consultant to the Company since that time. Mr. King is the former long-time Chief Business Officer and Chief Financial Officer of Aprecia Pharmaceuticals, LLC.